Opko Launches Validation Study for 4Kscore Prostate Cancer Test, Aims to Start US Sales in Q1 2014 | GenomeWeb

Opko Health said this week that is has begun a multi-center clinical validation study to support the launch of its 4Kscore protein biomarker prostate cancer test.

The company has begun enrolling patients at the first of 13 US-based clinical sites with the goal of enrolling more than 1,200 subjects over the next few months and plans to launch the test in the first quarter of 2014, David Okrongly, president of Opko Diagnostics, said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.